Market Research Logo

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

Systemic Lupus Erythematosus - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Systemic Lupus Erythematosus - Pipeline Review, H2 2015’, provides an overview of the Systemic Lupus Erythematosus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Systemic Lupus Erythematosus Overview
Therapeutics Development
Pipeline Products for Systemic Lupus Erythematosus - Overview
Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis
Systemic Lupus Erythematosus - Therapeutics under Development by Companies
Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes
Systemic Lupus Erythematosus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Systemic Lupus Erythematosus - Products under Development by Companies
Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc.
Ablynx NV
Actelion Ltd
AiCuris GmbH & Co. KG
Amgen Inc.
Anthera Pharmaceuticals‚ Inc.
Argos Therapeutics, Inc.
Biogen, Inc.
Biotest AG
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Chong Kun Dang Pharmaceutical Corp.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Genosco
Genovax S.r.l.
GlaxoSmithKline Plc
Hansa Medical AB
ImmuNext, Inc.
Immunomedics, Inc.
Immupharma Plc
Invion Limited
Johnson & Johnson
Kadmon Corporation, LLC
Karyopharm Therapeutics, Inc.
Kineta, Inc.
Lead Discovery Center GmbH
MacroGenics, Inc.
MedAnnex Ltd
MedImmune, LLC
Medsenic
Merck KGaA
Mitsubishi Tanabe Pharma Corporation
Neovacs SA
Nippon Chemiphar Co., Ltd.
Ocata Therapeutics, Inc.
Padlock Therapeutics, Inc.
Pfizer Inc.
Plexxikon Inc.
Principia Biopharma Inc.
RedHill Biopharma Ltd.
Redx Pharma Plc
Resolve Therapeutics, LLC
Sanofi
Sarepta Therapeutics, Inc.
SBI Biotech Co., Ltd.
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Therapix Biosciences Ltd
UCB S.A.
Xencor, Inc.
XTL Biopharmaceuticals Ltd.
Systemic Lupus Erythematosus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(rifabutin + clarithromycin + clofazimine) - Drug Profile
abatacept - Drug Profile
ABBV-084 - Drug Profile
ABS-11 - Drug Profile
ACT-334441 - Drug Profile
AGS-009 - Drug Profile
AIC-284 - Drug Profile
ALX-0061 - Drug Profile
AMG-557 - Drug Profile
AMG-729 - Drug Profile
AMG-811 - Drug Profile
anifrolumab - Drug Profile
Annexuzlimab - Drug Profile
Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus - Drug Profile
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
arsenic trioxide - Drug Profile
AT-791 - Drug Profile
atacicept - Drug Profile
BB-004 - Drug Profile
belimumab - Drug Profile
BIIB-059 - Drug Profile
blisibimod - Drug Profile
brentuximab vedotin - Drug Profile
BT-063 - Drug Profile
CC-220 - Drug Profile
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile
CKD-506 - Drug Profile
dalazatide - Drug Profile
dapirolizumab pegol - Drug Profile
Drug to Inhibit PAD for Autoimmune Diseases, CNS and Oncology - Drug Profile
E-6446 - Drug Profile
edratide - Drug Profile
Endoglycosidase of Streptococcus pyogenes - Drug Profile
forigerimod acetate - Drug Profile
GNKS-356 - Drug Profile
GX-101 - Drug Profile
IGM-001 - Drug Profile
IMP-10 - Drug Profile
INV-103 - Drug Profile
JB-6121 - Drug Profile
KD-025 - Drug Profile
KPT-350 - Drug Profile
Leukothera - Drug Profile
lulizumab pegol - Drug Profile
MGD-010 - Drug Profile
milatuzumab - Drug Profile
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
MT-1303 - Drug Profile
NC-2400 - Drug Profile
NCS-613 - Drug Profile
PF-04236921 - Drug Profile
PRN-1008 - Drug Profile
Recombinant Proteins for Systemic Lupus Erythematosus - Drug Profile
RN-486 - Drug Profile
RO-5461111 - Drug Profile
RSLV-132 - Drug Profile
RSLV-133 - Drug Profile
SAR-113244 - Drug Profile
SBI-3150 - Drug Profile
sifalimumab - Drug Profile
SM-101 - Drug Profile
SM-934 - Drug Profile
Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile
Small Molecule to Inhibit Immunoproteasome Subunit LMP7 for Autoimmune Disorders and Viral Infections - Drug Profile
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile
Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus and Rheumatoid Arthritis - Drug Profile
Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases - Drug Profile
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
Stem Cell Therapy for Systemic Lupus Erythematosus - Drug Profile
Synthetic Peptide for Systemic Lupus Erythematosus - Drug Profile
Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile
TAK-079 - Drug Profile
TAK-114 - Drug Profile
TAM-01 - Drug Profile
ustekinumab - Drug Profile
Vaccine for Systemic Lupus Erythematosus - Drug Profile
Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis - Drug Profile
venetoclax - Drug Profile
VISTA-Ig - Drug Profile
XmAb-5871 - Drug Profile
Y-27 - Drug Profile
Systemic Lupus Erythematosus - Recent Pipeline Updates
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H2 2015
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Systemic Lupus Erythematosus - Pipeline by 4SC AG, H2 2015
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2015
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2015
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co. KG, H2 2015
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Biogen, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2015
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2015
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2015
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2015
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2015
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2015
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2015
Systemic Lupus Erythematosus - Pipeline by Hansa Medical AB, H2 2015
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2015
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2015
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2015
Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2015
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Kineta, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2015
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2015
Systemic Lupus Erythematosus - Pipeline by MedImmune, LLC, H2 2015
Systemic Lupus Erythematosus - Pipeline by Medsenic, H2 2015
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2015
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2015
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015
Systemic Lupus Erythematosus - Pipeline by Ocata Therapeutics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Padlock Therapeutics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Plexxikon Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2015
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2015
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2015
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2015
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2015
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd, H2 2015
Systemic Lupus Erythematosus - Pipeline by UCB S.A., H2 2015
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2015
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Systemic Lupus Erythematosus Therapeutics - Recent Pipeline Updates, H2 2015
Systemic Lupus Erythematosus - Dormant Projects, H2 2015
Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2015
Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2015
Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2015
Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2015
Systemic Lupus Erythematosus - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H2 2015
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report